IQV vs PRA vs UNH vs CRL vs CVS

For growth investors, UnitedHealth Group Incorporated (UNH) is the stronger pick with 11.

8% revenue growth year-over-year, versus -2. 7% for ProAssurance Corporation (PRA). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 22. 8x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +17.

0%, compared to -46. 9% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: UNH returned +220. 6% versus PRA's -18. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ProAssurance Corporation (PRA) is the lower-risk stock at 0.

05β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 3064% more volatile than PRA relative to the S&P 500. On balance sheet safety, ProAssurance Corporation (PRA) carries a lower debt/equity ratio of 32% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), UnitedHealth Group Incorporated (UNH) is pulling ahead at 11.

8% versus -2. 7% for ProAssurance Corporation (PRA). On earnings-per-share growth, the picture is similar: IQVIA Holdings Inc. grew EPS 4. 7% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, UNH leads at 11. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus 2. 6% for CVS. At the gross margin level — before operating expenses — PRA leads at 39. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CVS Health Corporation (CVS) trades at 12.

2x forward P/E versus 21. 8x for ProAssurance Corporation — 9. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 26. 3% to $225. 63.

In this comparison, CVS (3.

1% yield), UNH (2. 4% yield) pay a dividend. IQV, PRA, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, CRL: +119. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IQV (Healthcare) and PRA (Financial Services) and UNH (Healthcare) and CRL (Healthcare) and CVS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IQV is a mid-cap quality compounder stock; PRA is a small-cap quality compounder stock; UNH is a large-cap quality compounder stock; CRL is a small-cap quality compounder stock; CVS is a mid-cap income-oriented stock. UNH, CVS pay a dividend while IQV, PRA, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.